{"doi":"10.1056/nejmoa1916623","title":"The Effect of Advances in Lung-Cancer Treatment on Population Mortality","abstract":null,"journal":"New England Journal of Medicine","year":2020,"id":47241,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1755,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":25,"is_dataset":false,"is_dataset_confidence":0.9434,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":218024,"name":"Gonçalo Forjaz","orcid":"0000-0001-8855-2042","position":1,"is_corresponding":false},{"id":218025,"name":"Meghan J. Mooradian","orcid":"0000-0002-8289-8015","position":2,"is_corresponding":false},{"id":218026,"name":"Rafael Meza","orcid":"0000-0002-1076-5037","position":3,"is_corresponding":false},{"id":218027,"name":"Chung Yin Kong","orcid":"0000-0001-6431-7830","position":4,"is_corresponding":false},{"id":218028,"name":"Kathleen A. Cronin","orcid":"0000-0002-7282-9323","position":5,"is_corresponding":false},{"id":218029,"name":"Angela B. Mariotto","orcid":"0000-0003-2423-1834","position":6,"is_corresponding":false},{"id":218030,"name":"Douglas R. Lowy","orcid":"0000-0003-0635-219X","position":7,"is_corresponding":false},{"id":218031,"name":"Eric J. Feuer","orcid":"0000-0003-4842-7751","position":8,"is_corresponding":false},{"id":218023,"name":"Nadia Howlader","orcid":"0000-0002-1989-1478","position":0,"is_corresponding":true}],"reference_count":38,"raw_metadata":null,"created_at":"2026-07-18T14:18:31.320809Z","pmid":"32786189","pmcid":"PMC8577315","fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":"http://www.nejmgroup.org/legal/terms-of-use.htm","views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[{"doi":"10.6084/m9.figshare.14524759.v1","title":"Additional file 1 of KLF5-induced BBOX1-AS1 contributes to cell malignant phenotypes in non-small cell lung cancer via sponging miR-27a-5p to up-regulate MELK and activate FAK signaling pathway","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.14524759","title":"Additional file 1 of KLF5-induced BBOX1-AS1 contributes to cell malignant phenotypes in non-small cell lung cancer via sponging miR-27a-5p to up-regulate MELK and activate FAK signaling pathway","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16620687","title":"Additional file 1 of The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16620687.v1","title":"Additional file 1 of The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16620690.v1","title":"Additional file 2 of The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16620690","title":"Additional file 2 of The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16620693.v1","title":"Additional file 3 of The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16620693","title":"Additional file 3 of The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16807562.v1","title":"Additional file 10 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16807562","title":"Additional file 10 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16807565.v1","title":"Additional file 11 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16807565","title":"Additional file 11 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16807568.v1","title":"Additional file 12 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16807568","title":"Additional file 12 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16807571.v1","title":"Additional file 13 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16807571","title":"Additional file 13 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16807580.v1","title":"Additional file 3 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16807580","title":"Additional file 3 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16807583.v1","title":"Additional file 4 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16807583","title":"Additional file 4 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16807586.v1","title":"Additional file 5 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16807586","title":"Additional file 5 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16807589.v1","title":"Additional file 6 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16807589","title":"Additional file 6 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16807595.v1","title":"Additional file 7 of The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials","publisher":"figshare","resource_type":"JournalArticle"}],"topics":[{"topic_type":"mesh_term","value":"Humans","extra":null},{"topic_type":"mesh_term","value":"Carcinoma, Non-Small-Cell Lung","extra":null},{"topic_type":"mesh_term","value":"Lung Neoplasms","extra":null},{"topic_type":"mesh_term","value":"SEER Program","extra":null},{"topic_type":"mesh_term","value":"Incidence","extra":null},{"topic_type":"mesh_term","value":"Mortality","extra":null},{"topic_type":"mesh_term","value":"Sex Factors","extra":null},{"topic_type":"mesh_term","value":"United States","extra":null},{"topic_type":"mesh_term","value":"Female","extra":null},{"topic_type":"mesh_term","value":"Male","extra":null}]}